CI
ABMD

CX Institutional’s Abiomed Inc ABMD Stock Holding History

CX Institutional’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-47
Closed -$12K – 1184
2022
Q2 		$12K Buy
+47
New +$12.7K ﹤0.01% 928
2021
Q4 		– Sell
-91
Closed -$30K – 942
2021
Q3 		$30K Buy
91
+13
+17% +$4.4K ﹤0.01% 672
2021
Q2 		$24K Buy
78
+34
+77% +$10.4K ﹤0.01% 710
2021
Q1 		$14K Buy
44
+7
+19% +$2.24K ﹤0.01% 730
2020
Q4 		$12K Buy
37
+16
+76% +$4.43K ﹤0.01% 710
2020
Q3 		$6K Sell
21
-1
-5% -$288 ﹤0.01% 735
2020
Q2 		$5K Buy
+22
New +$4.42K ﹤0.01% 678
2019
Q4 		– Sell
-7
Closed -$1K – 783
2019
Q3 		$1K Buy
+7
New +$1.51K ﹤0.01% 788
2019
Q1 		– Sell
-2
Closed -$1K – 833
2018
Q4 		$1K Buy
+2
New +$695 ﹤0.01% 526

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return

CX Institutional's ABMD Position: Q3 2022 in Review

CX Institutional sold out of Abiomed Inc (ABMD) in Q3 2022, closing a stake of 47 shares — an estimated $12K sold.

CX Institutional first reported a position in ABMD in Q4 2018 and held it in 9 quarters. The position peaked at $30K in Q3 2021. 517 funds tracked by Wall St. Rank hold ABMD as of Q3 2022.

  • CX Institutional reported no remaining Abiomed Inc position as of Q3 2022 after selling out during the quarter.
  • CX Institutional sold 47 Abiomed Inc shares in Q3 2022, an estimated $12K.
  • CX Institutional first reported a position in Abiomed Inc in Q4 2018 and held it in 9 quarters.
  • CX Institutional's Abiomed Inc position peaked at $30K in Q3 2021.
  • 517 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2022.

Based on CX Institutional's 13F filing for Q3 2022, filed 4 Nov 2022.